e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Cellular and molecular aspects of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling
S. Hamidi, S. Said (Stony Brook, NY, Northport, NY, United States Of America)
Source:
Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Session:
Cellular and molecular aspects of pulmonary hypertension
Session type:
Electronic Poster Discussion
Number:
484
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Hamidi, S. Said (Stony Brook, NY, Northport, NY, United States Of America). Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling. Eur Respir J 2007; 30: Suppl. 51, 484
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion
Source: Eur Respir J 2008; 31: 135-139
Year: 2008
Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2006 - Cellular mechanisms of airway disease
Year: 2006
Pulmonary arterial hypertension phenotype in VIP knockout mice
Source: Eur Respir J 2006; 28: Suppl. 50, 546s
Year: 2006
Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Towards an understanding of pulmonary arterial hypertension (PAH): gene regulation patterns in pulmonary arterial resistance vessels of patients with PAH
Source: Eur Respir J 2006; 28: Suppl. 50, 526s
Year: 2006
Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension
Year: 2007
Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension
Source: Eur Respir J 2016; 48: 1668-1681
Year: 2016
In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
CFTR in the regulation of pulmonary vascular tone and remodeling
Source: Eur Respir J, 58 (6) 2101861; 10.1183/13993003.01861-2021
Year: 2021
Expression of fetal genes in pulmonary arterial hypertension
Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms
Year: 2005
Endothelial NO and its pathophysiologic regulation
Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease
Year: 2007
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 147s
Year: 2006
Role of c-Abelson in the loss of genome integrity in endothelial cells in pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
TrkB expression is altered in hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 606s
Year: 2007
IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension
Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept